Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Arzneimittel-Forschung|January 1, 1977
Serum and urine concentrations of rifampicin administered by intravenous infusion in manG Acocella, L Bonollo, M Mainardi, et al.
Giornale Italiano Di Chemioterapia|January 1, 1989
Past, present and future trends in tuberculosis epidemiology in a region of northern Italy. An analysis carried out through the application of a simulation model (Eskimo)G Acocella, E Comaschi, A Nonis, et al.
The American Review of Respiratory Disease|December 1, 1985
Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combinationN A Carlone, G Acocella, A M Cuffini, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1979
Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitroB P Goldstein, I F Ripamonti, G Bolzoni, et al.
The Journal of Antibiotics|August 1, 1981
Antibacterial activity of DL 473, a new semisynthetic rifamycin derivativeV Arioli, M Berti, G Carniti, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|January 1, 1993
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapyG Acocella, M Luisetti, G G Grassi, et al.
The American Review of Respiratory Disease|October 1, 1988
Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration studyG Acocella, A Nonis, G Perna, et al.
Giornale Italiano Di Chemioterapia|January 1, 1989
Eskimo: an epidemiological simulation kinetic model for tuberculosisG Acocella, W Pollini, L Pelati, et al.
Pharmacological Research Communications|July 1, 1984
Pharmacokinetic study on intravenous rifampicin in manG Acocella, G Segre, R Conti, et al.
Gut|January 1, 1972
Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver diseaseG Acocella, L Bonollo, M Garimoldi, et al.
Pageof 5